<div id="readability-page-1"><p>Y Intercept Hong Kong Ltd trimmed its position in shares of  Alkermes plc (NASDAQ:ALKS - Free Report) by 61.7% in the third quarter, according to its most recent 13F filing with the Securities &amp; Exchange Commission. The firm owned 53,067 shares of the company's stock after selling 85,366 shares during the period. Y Intercept Hong Kong Ltd's holdings in Alkermes were worth $1,592,000 at the end of the most recent quarter.</p><p>Several other large investors also recently made changes to their positions in the company. Capital Fund Management S.A. bought a new position in  Alkermes in the second quarter valued at approximately $1,142,000.  EcoR1 Capital LLC acquired a new position in shares of  Alkermes in the 2nd quarter valued at approximately $14,305,000.  Robeco Institutional Asset Management B.V. boosted its holdings in shares of  Alkermes by 18.6% in the third quarter. Robeco Institutional Asset Management B.V. now owns 134,387 shares of the company's stock valued at $4,032,000 after buying an additional 21,067 shares during the period.  Frazier Life Sciences Management L.P. increased its holdings in  Alkermes by 66.5% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 1,000,647 shares of the company's stock worth $28,629,000 after purchasing an additional 399,518 shares in the last quarter.  Finally, Magnetar Financial LLC bought a new position in shares of  Alkermes during the second quarter worth about $3,538,000. Institutional investors and hedge funds own  95.21% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><p>A number of equities research analysts have recently issued reports on ALKS shares. Piper Sandler  reiterated an &#34;overweight&#34; rating and set a $45.00 price objective (up previously from $38.00) on shares of Alkermes in a research note on Thursday, October 23rd. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Alkermes from $55.00 to $45.00 and set a &#34;buy&#34; rating on the stock in a report on Thursday, November 13th. Needham &amp; Company LLC increased their price target on shares of Alkermes from $43.00 to $44.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, October 29th. Zacks Research upgraded shares of Alkermes from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Tuesday, January 13th. Finally, Weiss Ratings  reiterated a &#34;hold (c+)&#34; rating on shares of Alkermes in a report on Monday, December 29th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned  a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $44.69.</p><p><b>Check Out Our Latest Research Report on ALKS</b></p><h2>Insiders Place Their Bets</h2><p>In other news, EVP Craig C. Hopkinson sold 5,000 shares of the business's stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $30.00, for a total transaction of $150,000.00. Following the sale, the executive vice president directly owned 61,740 shares in the company, valued at approximately $1,852,200. The trade was a 7.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last 90 days, insiders sold 25,748 shares of company stock worth $765,060. Insiders own  4.40% of the company's stock. </p><h2>Alkermes Trading Down 2.8%</h2><p>Shares of NASDAQ:ALKS opened at $33.89 on Friday. The firm has a 50 day moving average of $29.82 and a 200-day moving average of $29.38. Alkermes plc has a 12 month low of $25.17 and a 12 month high of $36.45. The stock has a market capitalization of $5.60 billion, a PE ratio of 16.78 and a beta of 0.48. </p><p>Alkermes (NASDAQ:ALKS - Get Free Report) last announced its quarterly earnings data on Tuesday, October 28th. The company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.08. Alkermes had a return on equity of 21.81% and a net margin of 22.27%.The business had revenue of $394.19 million during the quarter, compared to the consensus estimate of $355.23 million. During the same period in the prior year, the company earned $0.73 EPS. Alkermes's revenue for the quarter was up 4.3% on a year-over-year basis.  On average, research analysts predict that  Alkermes plc will post 1.31 EPS for the current fiscal year. </p><h2>Alkermes Company Profile</h2> (Free Report)<p>Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes' portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.  </p><p>Alkermes' commercial franchise features several approved products.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Alkermes</li><li>Do not delete, read immediately</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li><li>A U.S. “birthright” claim worth trillions - activated quietly</li><li>The Crash Has Already Started (Most Just Don’t See It Yet)</li></ul><p><strong>Want to see what other hedge funds are holding ALKS?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes plc (NASDAQ:ALKS - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxLUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxLUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Alkermes Right Now?</h2><p>Before you consider Alkermes, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alkermes wasn't on the list.</p><p>While Alkermes currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Y Intercept Hong Kong Ltd reduced its stake in Alkermes plc by 61.7% in Q3, holding 53,067 shares valued at $1.59 million. Other investors also adjusted their positions, with significant new investments and increases in holdings. Analysts have mixed ratings on Alkermes, with a consensus rating of "Moderate Buy" and a target price of $44.69. Alkermes shares opened at $33.89, down 2.8%, with a market cap of $5.60 billion. The company reported Q3 earnings of $0.49 per share, exceeding estimates, and revenue of $394.19 million, up 4.3% year-over-year.</p>

Market Beat

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

iShares Global Healthcare

VG Health

iShares US Pharma

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bear 3X

Ark Genomic Revolution ETF

iShares Biotechnology ETF

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Alkermes

Alkermes plc $ALKS Shares Sold by Y Intercept Hong Kong Ltd